Instruction for use: Amisulpride

The Latin name of the substance Amisulpride

Amisulpridum (genus. Amisulpridi)

Chemical name

4-Amino-N - [(1-ethyl-2-pyrrolidinyl) methyl] -5- (ethylsulfonyl) -2-methoxybenzamide

Gross formula

C₁₇H₂₇N₃O₄S

Pharmacological group:

Neuroleptics

The nosological classification (ICD-10)

F20 Schizophrenia: Schizophrenic conditions; Exacerbation of schizophrenia; Schizophrenia; Chronic schizophrenia; Dementia praecox; Bleuler's disease; Psychotic discordant; Dementia early; The febrile form of schizophrenia; Chronic schizophrenic disorder; Psychosis of the schizophrenic type; Acute form of schizophrenia; Acute schizophrenic disorder; Cerebral Organic Insufficiency in Schizophrenia; Acute attack of schizophrenia; Schizophrenic psychosis; Acute schizophrenia; Sluggish schizophrenia; Sluggish schizophrenia with apathoabulic disorders; Acute stage of schizophrenia with excitation

F23 Acute and transient psychotic disorders: Psychogenic psychosis; Psychosis acute; Short-term psychotic disorder

F42 Obsessive-compulsive disorder: Obsessive-compulsive syndrome; Obsessive compulsive states; Obsessive-compulsive syndrome; The obsession syndrome; The obsession neurosis; Obsessive-compulsive neurosis; Obsessions

R44.3 Hallucinations, unspecified: Hallucinatory conditions; Hallucinations; Acute hallucinatory state; Chronic hallucinatory conditions

R45.3 Demoralization and apathy: Apatiko-Abulian phenomenon; Apathy; Apatobulic conditions; Apathoabulic Disorder; Apatobulic state; Indifference; Bezynitsiativnost; Vyaloapaticheskoe condition; Sluggish-apathic state; Deficiency of motivations and motivations; Lack of initiative; Lack of emotionality and avoidance of communication; Feeling of inferiority; Decreased initiative; Decreased motivation; Reduced initiative

R46.4 Retardation and delayed reaction: Anergy; Inhibition; Ideal slowing; Motor retardation; Psychomotor retardation; The phenomena of ideomotor inhibition

CAS Code

71675-85-9

Pharmacology

Pharmacological action - antipsychotic.

Selectively blocks D2- and D3-dopaminergic receptors of the central nervous system. Reduces the severity of productive symptoms and inhibition.

Application of the substance Amisulpride

Acute and chronic schizophrenic disorders, accompanied by pronounced positive (delirium, hallucinations, thinking disorders, etc.) and / or negative (affective stupidity, lack of emotionality and avoiding communication, etc.) symptoms, including. for patients with a predominance of negative symptoms.

Contraindications

Hypersensitivity, pheochromocytoma, prolactin-dependent tumors (including prolactinoma of the pituitary gland), breast cancer, childhood and adolescence (up to 15 years).

Application in pregnancy and lactation

Use in pregnancy is not recommended, except when the expected effect of therapy exceeds the potential risk for the fetus (adequate and strictly controlled studies in pregnant women were not performed). Contraindicated in breastfeeding (it is not known whether amisulpride penetrates into breast milk).

Side effects of Amisulpride

From the nervous system and sensory organs: insomnia, anxiety, agitation, drowsiness, extrapyramidal disorders, tardive dyskinesia, convulsive seizures, malignant neuroleptic syndrome.

On the part of the digestive tract: constipation, nausea, vomiting, dry mouth.

Other: hyperprolactinemia (including pain in the mammary glands, amenorrhea, galactorrhea, gynecomastia, sexual dysfunction, impotence), weight gain, hypotension, bradycardia, prolongation of the QT interval on the ECG, increase in the level of hepatic transaminases, allergic reactions.

Interaction

It is an antagonist of levodopa. When combined with antihypertensive, some antihistamine and deprimiruyuschimi means (analgesics, general anesthetics, tranquilizers, alcohol, etc.) requires caution.

Routes of administration

Inside.

Precautions for the substance Amisulpride

With special care appoint with kidney failure, epilepsy, parkinsonism, elderly patients; during work drivers of vehicles and people whose profession is associated with increased concentration of attention. For the duration of treatment, alcohol intake is excluded.